[go: up one dir, main page]

MX2010004514A - Apolipoproteina a-1 y peptidos mimeticos resistentes a la oxidacion. - Google Patents

Apolipoproteina a-1 y peptidos mimeticos resistentes a la oxidacion.

Info

Publication number
MX2010004514A
MX2010004514A MX2010004514A MX2010004514A MX2010004514A MX 2010004514 A MX2010004514 A MX 2010004514A MX 2010004514 A MX2010004514 A MX 2010004514A MX 2010004514 A MX2010004514 A MX 2010004514A MX 2010004514 A MX2010004514 A MX 2010004514A
Authority
MX
Mexico
Prior art keywords
apolipoprotein
mimetic peptides
oxidant resistant
resistant
oxidant
Prior art date
Application number
MX2010004514A
Other languages
English (en)
Inventor
Jonathan D Smith
Stanley L Hazen
Original Assignee
Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Foundation filed Critical Cleveland Clinic Foundation
Publication of MX2010004514A publication Critical patent/MX2010004514A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un polipéptido purificado que incluye ApoA1 mimético o fragmento del mismo que son resistentes a la oxidación.
MX2010004514A 2007-10-23 2008-10-23 Apolipoproteina a-1 y peptidos mimeticos resistentes a la oxidacion. MX2010004514A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98188707P 2007-10-23 2007-10-23
PCT/US2008/080898 WO2009055538A1 (en) 2007-10-23 2008-10-23 Oxidant resistant apolipoprotein a-1 and mimetic peptides

Publications (1)

Publication Number Publication Date
MX2010004514A true MX2010004514A (es) 2010-07-28

Family

ID=40336739

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004514A MX2010004514A (es) 2007-10-23 2008-10-23 Apolipoproteina a-1 y peptidos mimeticos resistentes a la oxidacion.

Country Status (13)

Country Link
US (4) US8143224B2 (es)
EP (3) EP2212351B1 (es)
JP (1) JP5600065B2 (es)
KR (1) KR20100100824A (es)
CN (1) CN102177176B (es)
AU (1) AU2008316811B2 (es)
BR (1) BRPI0818881A2 (es)
CA (1) CA2703962A1 (es)
EA (1) EA201070517A1 (es)
ES (1) ES2601830T3 (es)
IL (1) IL205282A (es)
MX (1) MX2010004514A (es)
WO (1) WO2009055538A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010004514A (es) * 2007-10-23 2010-07-28 Cleveland Clinic Foundation Apolipoproteina a-1 y peptidos mimeticos resistentes a la oxidacion.
WO2011143362A1 (en) * 2010-05-11 2011-11-17 Esperion Therapeutics, Inc. Dimeric oxidation-resistant apolipoprotein a1 variants
CA2802388A1 (en) * 2010-06-15 2011-12-22 The Cleveland Clinic Foundation Compositions and methods for treating cancer
WO2012109162A1 (en) 2011-02-07 2012-08-16 Cerenis Therapeutics Holding S.A. Lipoprotein complexes and manufacturing and uses thereof
US9610324B2 (en) 2012-07-11 2017-04-04 Esperion Therapeutics, Inc. Apolipoprotein mixtures
WO2015032841A2 (en) * 2013-09-05 2015-03-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for prevention or treatment of th17 mediated disease
CN106488987A (zh) 2014-05-02 2017-03-08 塞勒尼斯医疗控股公司 Hdl疗法标志物
CN106573970B (zh) * 2014-05-15 2021-07-30 克利夫兰心脏实验室公司 用于hdl和apoa1的纯化和检测的组合物和方法
WO2017011312A1 (en) 2015-07-10 2017-01-19 Peptinovo Biopharma, Llc Formulations for improving the efficacy of hydrophobic drugs
US10484742B2 (en) * 2016-07-26 2019-11-19 Umbo, Inc. Method and system for providing information to a user via a projection device
ES2984285T3 (es) 2017-08-10 2024-10-29 Abionyx Pharma Sa Cargómeros
TW201919686A (zh) 2017-08-10 2019-06-01 法商塞勒尼斯醫療控股公司 脫輔基子(apomers)
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
US12292451B2 (en) 2018-06-08 2025-05-06 Cleveland Clinic Foundation ApoA1 exchange rate assays in serum
WO2021209823A1 (en) 2020-04-16 2021-10-21 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein- based complexes
CA3197168A1 (en) 2020-10-01 2022-04-07 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
MX2023012223A (es) 2021-04-15 2023-10-26 Abionyx Pharma Sa Uso de complejos a base de proteinas de union a lipidos en soluciones de conservacion de organos.
WO2023194797A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
CN119317440A (zh) 2022-04-06 2025-01-14 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗白细胞增多、内皮功能障碍和心脏炎的方法
CA3258787A1 (en) 2022-06-10 2023-12-14 Stanislas FAGUER METHODS OF TREATMENT OF HYPERINFLAMMATORY DISEASES USING LIPID-BINDING PROTEIN COMPLEXES
IL317446A (en) 2022-06-10 2025-02-01 Abionyx Pharma Sa Methods for treating acute conditions using complexes based on lipid-binding proteins
AU2024207875A1 (en) 2023-01-13 2025-07-24 Abionyx Pharma Sa Lipid binding protein molecule therapy
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
SE9203753D0 (sv) * 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
US20020064820A1 (en) * 2000-03-13 2002-05-30 Jean-Michel Dayer Apo-A-I regulation of T-cell signaling
US7144862B2 (en) * 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US20060030525A1 (en) 2004-07-23 2006-02-09 Xencor, Inc. Apolipoprotein A-I derivatives with altered immunogenicity
WO2007106938A1 (en) * 2006-03-20 2007-09-27 The University Of Queensland Method of treatment or prophylaxis inflammatory pain
MX2010004514A (es) * 2007-10-23 2010-07-28 Cleveland Clinic Foundation Apolipoproteina a-1 y peptidos mimeticos resistentes a la oxidacion.

Also Published As

Publication number Publication date
CN102177176B (zh) 2014-05-07
US20160024182A1 (en) 2016-01-28
EP2520587B1 (en) 2016-08-10
EA201070517A1 (ru) 2010-12-30
US9522950B2 (en) 2016-12-20
EP2573113A2 (en) 2013-03-27
US9051393B2 (en) 2015-06-09
US8536117B2 (en) 2013-09-17
CN102177176A (zh) 2011-09-07
EP2212351A1 (en) 2010-08-04
US20120264677A1 (en) 2012-10-18
EP2212351B1 (en) 2017-09-13
ES2601830T3 (es) 2017-02-16
US20090149390A1 (en) 2009-06-11
EP2520587A2 (en) 2012-11-07
AU2008316811B2 (en) 2015-01-22
IL205282A0 (en) 2010-12-30
EP2573113A3 (en) 2013-07-24
KR20100100824A (ko) 2010-09-15
JP2011500832A (ja) 2011-01-06
US8143224B2 (en) 2012-03-27
AU2008316811A1 (en) 2009-04-30
BRPI0818881A2 (pt) 2015-05-05
WO2009055538A1 (en) 2009-04-30
US20140051624A1 (en) 2014-02-20
EP2520587A3 (en) 2013-04-03
HK1162522A1 (en) 2012-08-31
JP5600065B2 (ja) 2014-10-01
CA2703962A1 (en) 2009-04-30
IL205282A (en) 2016-02-29

Similar Documents

Publication Publication Date Title
MX2010004514A (es) Apolipoproteina a-1 y peptidos mimeticos resistentes a la oxidacion.
SG170086A1 (en) Modified molecules which promote hematopoiesis
IL258724B (en) Modified fgf–21 polypeptides and their uses
MX338336B (es) Polipeptidos de insulina modificados y sus usos.
EA201300455A1 (ru) Полипептиды с пермеазной активностью
SI2190473T1 (sl) Peptid z zmanjšano tvorbo dimerov
CY1110734T1 (el) Μεθοδος παραγωγης μονιμων ανθρωπινων κυτταρικων σειρων
CY1118136T1 (el) Αναστολεις πρωτεασης hcv
UA103774C2 (uk) Модифіковані поліпептиди бичачого гранулоцитарного колонієстимулювального фактора (g-csf) та їх застосування
MX2012002565A (es) Purificacion de proteina mejorada a traves de una elucion de proteina a modificada.
SG10201407640PA (en) Hepatitis b virus specific antibody and uses thereof
EP2195331A4 (en) SYNTHETIC APOLIPOPROTEIN RECIPIENTS AND METHOD OF USE
MX2008011874A (es) Composiciones estabilizadas de polipeptidos.
PT1984517E (pt) Métodos para modular o conteúdo de manose de proteínas recombinantes
IN2012DN02589A (es)
PH12013501101B1 (en) Immunosuppressive polypeptides and nucleic acids
TW200624294A (en) Security document
MY169807A (en) Cancer-targeting peptides and uses thereof in cancer therapy
CO6430475A2 (es) Polipéptidos que tienen actividad de celulasa
MX2009013682A (es) Enlazador de fmoc polimerico hidrolizable.
MX2012006981A (es) Polipeptidos de somatotropina bovina modificados y sus usos.
CY1111630T1 (el) Παραγωγα κυτοκινων
UA110921C2 (uk) Пептид
EP2593546A4 (en) AFFINITY CLEANING OF RNA UNDER NATIVE CONDITIONS BASED ON LAMBDA BOX B / N PEPTIDE INTERACTION
MX2009009370A (es) Conjugados del complemento de peptido.

Legal Events

Date Code Title Description
FG Grant or registration